Potential role of the brain dopaminergic system in the regulation of cytochrome P-450 expression

Polish Journal of Pharmacology

Volumn 56, Issue 6, 2004, Pages 701-708

  Wójcikowski, Jacek ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Brain; Cytochrome P 450; Dopaminergic system; Liver; Regulation

Indexed keywords

5 METHOXYTRYPTAMINE; ADRENALIN; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C11; CYTOCHROME P450 2E1; CYTOCHROME P450 3A1; CYTOKINE; DOPAMINE; GLUCOCORTICOID; GROWTH HORMONE; HALOPERIDOL; INSULIN; INTERLEUKIN 2; INTERLEUKIN 6; LIOTHYRONINE; MELATONIN; PERGOLIDE; PHENOBARBITAL; PROLACTIN; RIFAMPICIN; SEROTONIN; SEX HORMONE; SPIPERONE; SULPIRIDE; THYROID HORMONE; UNINDEXED DRUG;

ADENOHYPOPHYSIS; DISEASE ASSOCIATION; DOPAMINERGIC SYSTEM; DRUG ANTAGONISM; DRUG METABOLISM; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME REGULATION; FEMINIZATION; GROWTH HORMONE RELEASE; HORMONAL REGULATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LIVER CELL; NONHUMAN; PARKINSON DISEASE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; RECEPTOR BINDING; REGULATORY MECHANISM; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; STEROID METABOLISM; THYROTROPIN RELEASE;

BRAIN; CYTOCHROME P-450 ENZYME SYSTEM; DOPAMINE; GENE EXPRESSION REGULATION, ENZYMOLOGIC;

EID: 14244265417     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Basu S, Dasgupta PS: Dopamine, a neurotransmitter, influences the immune system. J Neuroimmunol, 2000, 102, 113-124.
2. Bergeron RM, Serron SC, Rinehart JJ, Cawley GF, Backes WL: Pituitary component of the aromatic hydrocarbon-mediated expression of CYP2B and CYP2C11. Xenobiotica, 1988, 28, 303-312.
3. Bleu AM, Maurel P, Pichette V, Leblond F, du Suich P: Interleukin-1β, interleukin-6, tumor necrosis factor-α and interferon-γ released by viral infection and aseptic inflamation reduce CYP1A1, 1A2 and 3A6 expression in rabbit hepatocytes. Eur J Pharmacol, 2003, 473, 197-206.
4. Bokor M, Farago A, Schnabel R, Garam T: Relationship between the immune system and the diseases of the central nervous system. Ther Hung, 1992, 40, 51-57.
5. Castano A, Herrera AJ, Cano J, Machado A: The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha,IL-1 beta and IFN-gamma. J Neurochem, 2002, 81, 150-157.
6. Czyrak A, Maćkowiak M, Chocyk A, Fijał K, Wedzony K: Role of glucocorticoids in the regulation of dopaminergic neurotransmission. Pol J Pharmacol, 2003, 55, 667-674.
7. De Souza EB, Kuhar MJ: Dopamine receptors in the anterior lobe of the human pituitary gland: autoradiographic localization. Brain Res, 1984, 306, 391-395.
8. Fuller RW, Snoddy HD: Elevation of serum corticosterone concentrations in rats by pergolide and other dopamine agonists. Endocrinology, 1981, 109, 1026-1032
9. Fuller RW, Snoddy HD, Mason NR, Clemens JA, Bemis KG: Elevation of serum corticosterone in rats by dopamine agonists related in structure to pergolide. Neuroendocrinology, 1983, 36, 285-290.
10. Ganguli R, Rabin BS: Decreased interleukin-2 production in schizophrenic patients. Biol Psychiatry, 1989, 26, 427-430.
11. Ganguli R, Yang ZW, Shurin G, Chengappa KNR, Brar JS, Gubbi AV, Rabin BS: Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res, 1994, 51, 1-10.
12. Gonzales FJ, Lee YH: Constitutive expression of hepatic cytochrome P-450 genes. FASEB, 1996, 10, 1112-1117.
13. Goudreau JL, Falls WM, Lookingland KJ, Moore KE: Periventricular-hypophysial dopaminergic neurons innervate the intermediate but not the neural lobe of the rat pituitary gland. Neuroendocrinology, 1995, 62, 147-154.
14. Hanev K, Sasaki A, Yoshinaga K: Evidence for endogenous dopaminergic control of GH relase in man. Tohoku J Exp Med, 1981, 135, 103-108.
15. Hines RN, Luo T, Cresteil T, Ding R, Prough RA, Fitzpatrick JL, Ripp SL et al.: Molecular regulation of genes encoding xenobiotic-metabolizing enzymes: mechanisms involving endogenous factors. Drug Metab Dispos, 2001, 29, 623-633.
16. Hiroi T, Imaoka S, Funae Y: Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun, 1998, 249, 838-843.
17. Honkakoski P, Negishi M: Regulation of cytochrome P450 genes by nuclear receptors. Biochem J, 2000, 347, 321-337.
18. Jankovic BD, Maric D: In vivo modulation of immune system by encephalin. Int J Neurosci, 1990, 51, 167-169.
19. Jezova D, Jurcovicova J, Vigas M, Murgas K, Labrie F: Increase in plasma ACTH after dopaminergic stimulation in rats. Psychopharmacology, 1985, 85, 201-203.
20. Jezova D, Vigas M: Apomorphine injection stimulates β-endorphin, adrenocorticotropin, and cortisol relase in healthy man. Psychoneuroendocrinology, 1988, 13, 479-485.
21. Lal S, De La Vega C, Sourkes TL, Friesen HG: Effect of apomorphine on growth hormone, prolactin, luteinizing hormone, follicle-stimulating hormone levels in human serum. J Clin Edocrinol Metab, 1973, 37, 719-724.
22. Legraverend C, Mode A, Westin S, Strom A, Eguchi H, Zaphiropoulos PG, Gustafsson JA: Transcriptional regulation of rat P-450 2C gene subfamily members by the sexually dimorphic pattern of growth hormone secretion. Mol Endocrinol, 1992, 6, 259-266.
23. Lewis DFV: Substrate selectivity and metabolism. In: Cytochromes P450. Structures and Function. Taylor & Francis, London, New York, 2001, 76-117.
24. Liddle C, Goodwin BJ, George J, Tapner M, Farrell G: Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes. J Clin Endocrinol Metab, 1998, 83, 2411-2416.
25. Liddle C, Mode A, Legraverend C, Gustafsson JA: Constitutive expression and hormonal regulation of male sexually differentiated cytochromes P450 in primary cultured rat hepatocytes. Arch Biochem Biophys, 1992, 298, 159-166.
26. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res, 1995, 29, 141-152.
27. Matera L: Endocrine, paracrine and autocrine actions of prolactin on immune cells. Life Sci, 1996, 59, 599-614.
28. Männistö PT, Mattila J, Kaakkola S: Possible involvement of nigrostriatal dopamine system in the inhibition of thyrotropin secretion in the rat. Eur J Pharmacol, 1981, 76, 403-409.
29. Meltzer HY: Long-term effects of neuroleptic drugs on the neuroendocrine system. Adv Biochem Psychopharmacol, 1985, 40, 59-68.
30. Morgan ET: Regulation of cytochrome P450 during inflammation and infection. Drug Metab Rev, 1997, 29, 1129-1188.
31. Morley JE, Brammer GL, Sharp B, Yamada T, Yuwiler A, Hershman JM: Neurotransmitter control of hypothalamic-pituitary-thyroid function in rats. Eur J Pharmacol, 1981, 70, 263-271.
32. Mueller GP, Simpkins J, Meites J, Moore KE: Differential effects of dopamine agonists and haloperidol on the relase of prolactin, thyroid stimulating hormone, growth hormone, and luteinizing hormone in rats. Neuroendocrinology, 1976, 20, 121-135.
33. Murray M: Inhibition and induction of cytochrome P450 2B1 in rat liver by promazine and chlorpromazine. Biochem Pharmacol, 1992, 44, 1219-1222.
34. Müller EE, Pecile A, Felici M, Cocchi D: Norepinephrine and dopamine injection into lateral brain ventricle of the rat and growth hormone-releasing activity in the hypothalamus and plasma. Endocrinology, 1970, 86, 1376-1382.
35. Nair NP, Lal S, Iskandar HI, Etienne P, Wood PL, Guyda H: Effect of sulpiride, an atypical neuroleptic, on apomorphine-induced growth hormone secretion. Brain Res Bull, 1982, 8, 587-591.
36. Nissbrandt H, Bergquist F, Jonason J, Engberg G: Inhibition of cytochrome P450 2E1 induces an increase in extracellular dopamine in rat substantia nigra: a new metabolic pathway? Synapse, 2001, 40, 294-301.
37. Onaya T, Hashizume K: Effects of drugs that modify brain biogenic amine concentrations on thyroid activation induced by exposure to cold. Neuroendocrinology, 1976, 20, 47-52.
38. Pampori NA, Agrawal AK, Shapiro BH: Infusion of gender-dependent plasma growth hormone profiles into intact rats: effects of subcutaneous, intraperitoneal, and intravenous routes of rat and human growth hormone on endogenous circulating growth hormone profiles and expression of sexually dimorphic hepatic CYP isoforms. Drug Metab Dispos, 2001, 29, 8-16.
39. Pampori NA, Shapiro BH: Feminization of hepatic cytochrome P450s by nominal levels of growth hormone in the feminine plasma profile. Mol Pharmacol, 1996, 50, 1148-1156.
40. Pascussi JM, Gerbal-Chaloin S, Pichard-Garcia L, Daujat M, Fabre JM, Maurel P, Vilarem MJ: Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem Biophys Res Commun, 2000, 274, 707-713.
41. Pascussi JM, Maurel P, Vilarem MJ: Pathophysiological factors affecting CAR gene expression. 13th International Conference on Cytochromes P450. Biochemistry, Biophysics and Drug Metabolism. June 29-July 3, 2003, Prague, Czech Republic. Chemické Listy (Symposia , 2003, 97, S52.
42. Prough RA, Linder MW, Pinairen JA, Xiao GH, Falkner KC: Hormonal regulation of hepatic enzymes involved in foreign compound metabolism. FASEB, 1996, 10, 1369-1377.
43. Quatrochi LC, Guzelian PS: CYP3A regulation: from pharmacology to nuclear receptors. Drug Metab Dispos, 2001, 29, 615-622.
44. Ram PA, Waxman DJ: Pretranslational control by thyroid hormone of rat liver steroid 5 alpha-reductase and comparison to the thyroid dependence of two growth hormone-regulated CYP2C mRNAs. J Biol Chem, 1990, 265, 19223-19229.
45. Rane A, Liu Z, Levol R, Bjelfman C, Thyr C, Ericson H, Hansson T et al.: Differential effects of neuroleptic agents on hepatic cytochrome P-450 isoenzymes in the male rat. Biochem Biophys Acta, 1996, 1291, 60-66.
46. Schuetz EG, Schuetz JD, May B, Guzelian PS: Regulation of cytochrome P-450b/e and P-450p gene expression by growth hormone in adult rat hepatocytes cultured on a reconstituted basement membrane. J Biol Chem, 1990, 265, 1188-1192.
47. Schuetz EG, Wrighton SA, Barwick JL, Guzelian PS: Induction of cytochrome P450 by glucocorticoids in rat liver. J Biol Chem, 1984, 259, 1999-2006.
48. Sherman GP, Kim S, Benjamin F, Kolodny KD: Effect of chlorpromazine on serum growth hormone concentration in man. N Engl J Med, 1971, 284, 72.
49. Shimada M, Murayama N, Nagata K, Hashimoto H, Yamazoe Y: A specific loss of growth hormone abolished sex-dependent expression of hepatic cytochrome P450 in rats: reversal of the profiles by growth hormone-treatment. Arch Biochem Biophys, 1997, 337, 134-42.
50. Sidhu JS, Omieciński CJ: cAMP-associated inhibition of phenobarbital-inducible cytochrome P450 gene expression in primary rat hepatocyte cultures. J Biol Chem, 1995, 270, 12762-12773.
51. Siewert E, Bort R, Kluge R, Heinrich PC, Castell J, Jover R: Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent. Hepatology, 2000, 32, 49-55.
52. Sonderfan AJ, Arlotto MP, Dutton DR, McMillen SK, Parkinson A: Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch Biochem Biophys, 1987, 255, 27-41.
53. Stypula G, Kunert-Radek J, Stepień H, Zylińska K, Pawlikowski M: Evaluation of interleukins, ACTH, cortisol and prolactin concentration in the blood of patients with Parkinson's disease. Neuroimmunomodulation, 1996, 3, 131-134.
54. Sundseth SS, Alberta JA, Waxman DJ: Sex-specific, growth hormone-regulated transcription of the cytochrome P450 2C11 and 2C12 genes. J Biol Chem 1992, 267, 3907-3914.
55. Tinel M, Elkahwaji J, Robin MA, Fardel N, Descatoire V, Haouzi D, Berson A et al.: Interleukin-2 over-expresses c-myc and down-regulates cytochrome P-450 in rat hepatocytes. J Pharmacol Exp Ther, 1999, 289, 649-655.
56. Vijayan E, Krulich L, McCann SM: Catecholamic regulation of TSH and growth hormone relase in ovariectomized and steroid-primed rats. Neuroendocrinology, 1978, 26, 174-185.
57. Warren GW, Poloyac SM, Gary DS, Mattson MP, Blouin RA: Hepatic cytochrome P-450 expression in tumor necrosis factor-alpha receptor (p55/p75) knock-out mice after endotoxin administration. J Pharmacol Exp Ther, 1999, 288, 945-950.
58. Waxman DJ: Interactins of hepatic cytochromes P450 with steroid hormones. Biochem Pharmacol, 1988, 37, 71-84.
59. Waxman DJ, Ram PA, Notani G, LeBlanc GA, Alberta JA, Morrissey JJ, Sundseth SS: Pituitary regulation of the male-specific steroid 6β-hydroxylase P-450 2a (gene product IIIA2) in adult rat liver. Suppresive influence of growth hormone and thyroxine acting at a pretranslational level. Mol Endocrinol, 1990, 4, 447-454.
60. Waxman DJ, Ram PA, Pampori NA, Shapiro BH: Growth hormone regulation of male-specific rat liver P450 2A2 and 3A2: induction by intermittent growth hormone pulses in male but not female rats rendered growth hormone deficient by neonatal monosodium glutamate. Mol Pharmacol, 1995, 48, 790-797.
61. Wolterboer HM, De Kruif CA, van Iersel AAJ, Falke HE, Nordhoek J, Blaauboer BJ: Comparison of cytochrome P-450 isoenzyme profiles in rat liver and hepatocyte cultures. Biochem Pharmacol, 1991, 42, 381-390.
62. Wróbel A, Nowak G, Ossowska G, Danilczuk Z, Zebrowska-Łupina I, Wielosz M: Effect of chronic treatment with dexamethasone on brain dopamine receptors in mice. Pol J Pharmacol, 2004, 56, 399-405.
63. Yamazoe Y, Ling X, Murayama N, Nagata K, Kato R: Modulation of hepatic level of microsomal testosterone 7 alpha-hydroxylase, P-450a (P450IIA), by thyroid hormone and growth hormone in rat liver. J Biochem, 1990, 108, 599-603.
64. Yamazoe Y, Murayama N, Shimada M, Kato R: Thyroid hormone suppression of hepatic levels of phenobarbital-inducible P-450b and P-450e, and other neonatal P-450s in hypophysectomized rats. Biochem Biophys Res Commun 1989, 160, 609-614.
65. You AM, Idle JR, Byrd LG, Krausz KW, Kupfer A, Gonzalez FJ: Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics, 2003, 13, 173-181.
66. Zaphiropoulos PG, Mode A, Norstedt G, Gustafsson JA: Regulation of sexual differentiation in drug and steroid metabolism. Trends Pharmacol Sci, 1989, 10, 149-153.